Earnings call transcript: Merit Medical Systems beats Q1 2026 expectations

Merit Medical delivered a Q1 2026 earnings beat, with EPS of $0.86 vs. $0.83 expected and revenue of $381.9 million vs. $377.81 million expected; shares rose 5.24% in aftermarket trading. Non-GAAP operating margin hit a record Q1 19.7% and free cash flow was $25 million, while management maintained 2026 EPS guidance of $4.01-$4.15 despite a projected $15 million tariff headwind. The View Point Medical acquisition and new product launches in oncology and endoscopy support the company’s growth outlook.

Analysis

MMSI is not being rerated just on an earnings beat; the setup is a cleaner mix story. The market is likely underappreciating how much margin expansion can come from portfolio pruning plus higher-quality tuck-ins: divesting low-margin revenue while adding higher-gross-margin therapeutic assets should mechanically lift operating leverage even if top-line growth stays mid-single digits.

The bigger second-order effect is that management is intentionally reclassifying the company around therapeutic vs foundational businesses, which should reduce the market’s tendency to value MMSI like a stagnant disposables supplier. If investors start underwriting the oncology/endoscopy platforms as multi-year share-takers rather than one-off products, the multiple can expand before the revenue inflects fully, especially with cash flow staying ahead of EPS. That matters because the stock is still pricing in execution risk from tariffs and OEM lumpiness, not the improved quality of earnings.

The key risk is timing: tariff relief is not yet in hand, and the guide still embeds a meaningful gross-margin headwind for several quarters. If reimbursement on prior tariffs is delayed or denied, the upside from operating discipline can get partially offset, and the stock may revert to a range-trade until the next update in mid-year. Also, the View Point acquisition is accretive only on a longer horizon, so any stumble in integration or channel adoption would hit the bull case quickly.

Contrarian view: the consensus may be too focused on the near-term EPS bridge and not enough on the platform architecture change. The market often pays for visible revenue acceleration, but here the more durable rerating catalyst is evidence that multiple smaller businesses are becoming category leaders with better margin profiles. That makes this a better 6-12 month compounder than a one-quarter earnings trade.

Key Decisions for Investors

• Long MMSI on any post-earnings pullback over the next 2-6 weeks; target a rerating to the low end of analyst targets as the market digests improved mix and margin quality. Risk is tariff noise delaying multiple expansion.
• Buy MMSI Jan-2027 calls or call spreads to express the longer-dated View Point/oncology upside; payoff improves if the market starts capitalizing the 2027 accretion story before the integration is fully visible.
• Pair trade: long MMSI / short a lower-growth med-tech peer with weaker margin structure over the next 3-6 months. The relative trade benefits if investors reward portfolio quality and disciplined capital allocation over simple top-line scale.
• Consider a tactical hedge with short-term put protection into the mid-year tariff update; catalyst window is the June/July commentary when management revisits the tariff assumption and could reset expectations either direction.